rigosertib in combination with azacitidine: a potential treatment for aml?
Published 7 years ago • 800 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
1:40
pivekimab sunirine in combination with venetoclax and azacitidine for cd123-positive aml
-
1:35
phase i study of plx51107, a novel bet inhibitor, in combination with azacitidine in r/r mds and aml
-
2:44
phase ib/ii study of magrolimab in combination with azacitidine and venetoclax in patients with aml
-
1:37
a phase i/ii trial of seclidemstat in combination with azacitidine for patients with mds and cmml
-
3:53
investigating the combination of pivekimab sunirine, azacitidine & venetoclax in r/r aml
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
2:27
emavusertib in combination with azacitidine and venetoclax in patients with aml
-
1:32:42
mds & covid-19 vaccine
-
1:48:46
journal club and journal scan
-
7:43
exploring a therapy called jakafi® (ruxolitinib)
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
2:39
a phase ii trial of ruxolitinib and azacitidine combination therapy in patients with myelofibrosis
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
1:19
novel combination therapy for cmml: jak inhibitor pacritinib plus azacitidine
-
4:44
establishing the clinical benchmark of azacitidine in patients with mds
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv
-
1:13
the use of azacitidine in hr-mds and the potential of combination therapies
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml